Market Overview

UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at Hold; Royalty Burden High

Share:
Related INFI
JPM Securities Picks Through Biotech News For Winners
UPDATE: Infinity Pharmaceuticals Posts Q4 Loss

Stifel Nicolaus initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Hold rating.

Stifel Nicolaus noted, "Infinity's phosphoinositide-3-kinase (PI3K) inhibitor, IPI-145, has the potential to be a best-in-class drug for one of the most exciting targets in oncology and inflammation treatment. Preclinical data for IPI-145 as well as data from other drugs in development validate the PI3K target in our opinion as one that will provide strong efficacy in tumor resistance and inflammation reduction, while retaining a favorable safety profile. IPI-145 is the only dual PI3K delta and gamma inhibitor currently in clinical trials."

Infinity Pharmaceuticals closed at $17.74 on Thursday.

Latest Ratings for INFI

DateFirmActionFromTo
Jan 2015Morgan StanleyDowngradesOverweightEqualweight
Dec 2014Credit SuisseUpgradesNeutralOutperform
Nov 2014NomuraMaintainsNeutral

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...